Thank you and welcome to the presentation of Nolato's fourth quarter of 2025. Starting on page 2, we had a sales that totaled just shy of 2.3 billion in the quarter, which gives a growth of approximately 2% adjusted for currency.

We saw an increased growth rate for the Medical Solutions business area at 5%, and we saw a decrease of approximately 1% for Engineered Solutions adjusted for currency. We had some headwinds on the sales in the last part of the quarter due to Christmas holidays and during that time.

Our operating profit ended up at 236 million, in comparison to 240. This was strongly affected by currency headwinds of 6%.

The margin rose to 10.4. We saw improved margins in both areas, but sequentially lower due to somewhat weaker volumes during the Christmas break, and also some start-ups cost for the new programs in United States.

If we focus on the full year of 2025, we ended up at close to 9.5 billion in sales. That was corresponding to a 2% increase adjusted for currency.

We saw an operating profit increase 11%, even though we had a strong currency headwind. The margin improved and end up at 11.3% in comparison to 9.9, we saw full 1.4 percentage points increase of margin.

The earnings per share ended up at 2.88 SEK per share, and we have a very strong financial position enabling us to execute on our increased acquisition strategy. The dividend proposal is 1.7 in comparison to 1.5 krona per share, and that is a current payout ratio of 59 in comparison to 61 last year.

If we jump to page 5, starting with Medical Solutions, here we are on a growth and global expansion journey, and this business area now corresponds to 58% of group sales in fourth quarter. On page 6, we see our focused product areas.

We feel that we are very well positioned with leading global customers and positioned in very interesting product areas. If we go through them a little quickly, we see the in vitro diagnostics with a long-term growth potential, and we have a very strong position in this therapeutical area.

Cardiology, of course, high-end market, a lot of lifetime implants, and very high demands on the products delivered. Drug delivery, growth market area where we have a very strong position and well positioned for continuously growth.

Endoscopy and general surgery, it's an changing market. It's interesting with the new sort of more robotic surgery that are coming in.

Continence care, of course, high-volume market with huge volumes. If we then jump into the fourth quarter for Medical Solutions, we ended up just above 1.3 billion in sales, which corresponds to 5% adjusted currency growth.

We see that the drug delivery market continued to exhibit growth within the autoinjector and pen injector systems. We saw a positive development for the in vitro diagnostic during the year, with a slow start last year and then increasing volumes.

If we look on the margin side, we ended up at 11.6% margin for the business area. That is an improvement of 0.4 percentage points compared to 2024.

We had during the quarter negative impact due to temporarily high costs for the start-ups, as mentioned before, and also some volume headwinds during the Christmas breaks. Our expansions are going according to plan, both in Hungary, Poland, and Malaysia.

Jumping into Engineered Solution, which is a sales level of close to billion and 42% of group sales in fourth quarter. In this area, we are focusing on different product areas.

Of course, the consumer electronics, where we see potentials, hygiene, good potentials, and automotive, of course, a little bit slow right now, as we explained in previous quarters. Then as a little bit different market, the materials, where we see strong growth, but also affected during this quarter by the increased cost of precious materials.

Jumping to the next page and then summarizing Engineered Solutions for the fourth quarter, as mentioned, strong growth materials, 10% increase if we adjust for the currency. We saw sustained performance for consumer electronic, particularly in Asia.

After a positive performance during the year, volumes decreased for hygiene in the last quarter due to an inventory adjustments ahead of year-end. The total business area ended up at an margin of 9.9 in comparison to 9.2.

We saw, of course, favorable product mix, but if we compare to the previous quarters of 2025, we had negative impact of the lower volumes and sharply increased precious metal prices, as mentioned.

Good afternoon, Per-Ola Holmström, CFO, and group financial highlights on page 11. Net sales was 2 billion 272 million in the quarter, a 2% growth given currency headwinds of 7%.

Operating profit EBITA amounted to 236 million, slightly below last year, but with currency headwinds of 6%, representing an accelerating negative effect of about 14 million SEK in the fourth quarter. The EBITA margin for the full year 2025 improved by 1.4 percentage points, driven by pricing, cost adjustments, and efforts in the entire supply chain.

The quarter improved 0.3 percentage points to 10.4%. The declined margin compared to previous quarters 2025 was negatively affected by: one, temporarily higher costs for start-up of the new products in the US (the medical margin was negatively affected by that by 0.5 percentage points); two, slightly lower volumes within mainly Engineered due to holidays at year-end; three, sharply increased prices for precious metals within materials in business area Engineered.

Summarizing these two effects for Engineered, the total negative effect is 1.0 percentage points for the business area. Four, group cost was on the high side in Q4 and, in comparison to Q3 that had one-offs of plus 7 million SEK, in addition, effects from M&A activities in Q4 giving a delta of 10 million SEK compared to Q3.

Summarizing these four items, the temporary negative effect is in the range of 25 to 30 million SEK compared to Q3. Parts of these will influence the first quarter 2026 as well.

Cash flow from operating activities was 310 million, a good level in the quarter, but last year was very positive from improved working capital. Net investments, we did see a shift in trends, CapEx declined compared to the comparing quarter last year to 146 million.

The full year 2026 is expected to be between 650 to 700 million, where 100 approximately still is left for the Hungarian project. Return on capital employed for the full year improved to 14.2%.

Turning to page 13—no, sorry, jumping, turning to page 12, sorry. Sustainable development, we have had a very positive development of our all kinds of measurements on the sustainable side.

If we focus first on our Scope 1 and 2 emissions, we have reduced this by 96% in absolute terms from our base year 2025 versus our target of 70% for 2020. It's an impressive journey on that side.

If we talk about Scope 3 upstream emissions, we have reduced that by 30% in absolute terms from the same base year versus our target of 25. We are well ahead of our near-term targets on path towards 2030.

We're also delivering fast result on our Science Based Target initiatives, and our net-zero targets for 2045 is approved by Science Based Target initiative in January of this year. Turning to page 13, focusing on our current situation.

Overall, we see very favorable financial position that enables intensified M&A agenda. Focusing on Medical Solutions, we have a continuous growth strategy.

We see very high market activity. We have a very strong, broad customer base with long-standing close customer relationships, enabled us to continue our growth journey.

Our establishments of operations in Malaysia and an expansion in Poland and as well as in in Hungary are creating excellent opportunities for us. Within the Engineered Solutions business area, we are advancing our market positions.

We have established position in new product areas, and successful in new products and technology areas, mainly data center is very positive for materials, and also the expansion of our operations in Malaysia creating opportunities. We are now handling over for questions.

Hi, it's Carl here from Nordea. Sorry for a slow unmuting.

A couple of questions here. It is of course a lot of dynamics in this report, I hope to unpack some of them.

You mentioned 100 basis points in Engineered owing to shutdowns as well as the precious material thing. Firstly, I wonder what materials are we talking about?

Secondly, yeah, how do you view that topic specifically for Q1 and Q2?

We could see that the pricing we are talking about that is affecting materials. As we are compounding a material which is including metal particles.

Some of these materials within that part is based on silver particles. As you have seen, pricing of that has skyrocketed during the fourth quarter, and it has continued in the beginning of January as well.

That is a part where we have quite short actions to change the pricing to our customers, and we are of course in the process of doing that. It's more standard materials which we are handling, and that will give effect.

Of course there is a timing effect, and as you have seen, pricing have continued up in the beginning of January as well, however now declining. We are in the middle of a very dynamic pricing because of the silver materials mainly.

That is affecting that part.

What portion of the 100 basis points was the metal or material thing compared to the customer earlier shutdowns?

That is the larger part of the 1%.

What did you say about Q1? Is it same effect or less effect or ballpark?

We do see that that will continue in Q1 as well, but it's slowing down a bit during the end of the quarter. That is our assumption based on pricing activities that we have done.

Then of course we don't know the ongoing pricing dynamics for the silver pricing going forward, but as far as we can see right now, that will be an effect which is slowing down during the rest of the quarter.

That's very clear. Jumping into Medical, you mentioned the production ramp-up in the US, the 50 basis points impact.

How long is that ramp, and is it a multi-product facility, or what are you ramping?

It's a multi things. There are different programs ramping at the same time, and we are expecting that to continue a little bit into the first quarter, and then of course be more steady state.

Good. The final question, if I may, is on the Medical organic growth.

Did the new autoinjector contract that you're manufacturing in Hungary contribute with a similar magnitude as in Q3? If so, what is the main delta behind the acceleration of the organic growth in Medical?

It's continuing. The new program in Hungary is continuing on the same level as in the third quarter, and also expected to continue on the same level in the first quarter of 2026.

Then it's a general thing. We have a growth in different areas, all kinds all over the place more or less.

Sorry, final one. In terms of the M&A cost you touched upon, it is a little bit on the high side given your history of doing due diligence.

Is it fair to assume that it's a bigger transaction, or is it several small ones you're looking into?

The delta of the 10 million is coming from seven from the one-time positive effect in Q3, and then the rest is mainly coming from these activities. Large or not large, but yeah, nothing peculiar,

I would say. Fair, understand.

Very good. Thank you.

All for me.

Thank you.

Hello, sorry, wasn't able to mute myself. I just had one question on the volumes.

Assuming that there were earlier shutdowns in Q4, do you expect to see a catch-up effect in Q1, or is it more of a normalized quarter?

I think we would see the first quarter as a more normalized quarter.

All right, I see. Then just on the start-up costs there in the US, any particular reason why you sort of highlight that as a temporary cost?

I suppose that you're looking to expand most of the time.

It was just an explanation to that we have several things running, and it was more than normal.

All right, I see. Then just I think a follow-up on Karl's question before, but just a clarification on the pricing adjustments in materials in specific.

How would you handle the dynamics of price increases when we have so volatile precious metal prices?

Yes, of course, if you have an upwards trend, it's something that then you have to adjust and do it right timing, and it's always a dynamic process, and you can't really go back to a customer every day. Then you might lose some temporarily on the upgoing if it's a continuous upwards trend.

All right, but have you done any price increases thus far based on the higher material prices that we saw especially in Q4?

Yes, we have.

All right. Perfect, that was all.

Thanks.

Thank you.

Thank you.